Detalles de la búsqueda
1.
Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Invest New Drugs
; 33(1): 119-27, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25242374
2.
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Cancer Sci
; 101(1): 210-5, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19832844
3.
E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities.
J Pharmacol Exp Ther
; 331(2): 485-95, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19684251
4.
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Vasc Cell
; 6: 18, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25197551
Resultados
1 -
4
de 4
1
Próxima >
>>